Advertisement

Whole-Slide Imaging of Esophageal Squamous Cell Carcinoma

  • Alfred K. LamEmail author
  • Melissa Leung
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2129)

Abstract

Whole-slide imaging (WSI) contributes to medical education, collaboration, quality assurance, examination, and consultation in pathology. The images obtained from WSI are of high quality and could be stored indefinitely. In research involving esophageal squamous cell carcinoma, the combination of WSI and image processing program allows effective interpretations of expressions of various immunomarkers related to pathogenesis, prognosis, and response to therapy in tissue microarray sections. The operation and basic principles of whole-slide imaging of esophageal squamous cell carcinoma are also presented. Common use of WSI will occur with modifications of the whole-slide imaging scanners to adapt to the workflows in diagnostic and research laboratories.

Key words

Whole-slide imaging Scanning Ki-67 Esophageal Squamous carcinoma Image analysis TMA 

References

  1. 1.
    Zarella MD, Bowman D, Aeffner F, Farahani N, Xthona A, Absar SF, Parwani A, Bui M, Hartman DJ (2019) A practical guide to whole slide imaging: a white paper from the digital pathology association. Arch Pathol Lab Med 143:222–234.  https://doi.org/10.5858/arpa.2018-0343-RACrossRefPubMedGoogle Scholar
  2. 2.
    Lam AK, Leung M (2018) Whole-slide imaging for esophageal adenocarcinoma. Methods Mol Biol 1756:135–142.  https://doi.org/10.1007/978-1-4939-7734-5_12.CrossRefPubMedGoogle Scholar
  3. 3.
    Gopalan V, Kasem K, Pillai S, Olveda D, Ariana A, Leung M, Lam AKY (2018) Evaluation of multidisciplinary strategies and traditional approaches in teaching pathology in medical students. Pathol Int 68:459–466.  https://doi.org/10.1111/pin.12706CrossRefGoogle Scholar
  4. 4.
    Van Es SL (2019) Digital pathology: semper ad meliora. Pathology 51:1–10.  https://doi.org/10.1016/j.pathol.2018.10.011CrossRefPubMedGoogle Scholar
  5. 5.
    Evans AJ, Bauer TW, Bui MM, Cornish TC, Duncan H, Glassy EF, Hipp J, McGee RS, Murphy D, Myers C, O'Neill DG, Parwani AV, Rampy BA, Salama ME, Pantanowitz L (2018) US food and drug administration approval of whole slide imaging for primary diagnosis: a key milestone is reached and new questions are raised. Arch Pathol Lab Med 142:1383–1387.  https://doi.org/10.5858/arpa.2017-0496-CPCrossRefPubMedGoogle Scholar
  6. 6.
    Cima L, Brunelli M, Parwani A, Girolami I, Ciangherotti A, Riva G, Novelli L, Vanzo F, Sorio A, Cirielli V, Barbareschi M, D’Errico A, Scarpa A, Bovo C, Fraggetta F, Pantanowitz L, Eccher A (2018) Validation of remote digital frozen sections for cancer and transplant intraoperative services. J Pathol Inform 9:34.  https://doi.org/10.4103/jpi.jpi_52_18CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wang H, Zhou Y, Liu Q, Xu J, Ma Y (2018) Prognostic value of SOX2, Cyclin D1, P53, and ki-67 in patients with esophageal squamous cell carcinoma. Onco Targets Ther 11:5171–5181.  https://doi.org/10.2147/OTT.S160066.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sunpaweravong S, Puttawibul P, Sunpaweravong P, Nitiruangjaras A, Boonyaphiphat P, Kemapanmanus M (2016) Correlation between serum SCCA and CYFRA 2 1-1, tissue Ki-67, and clinicopathological factors in patients with esophageal squamous cell carcinoma. J Med Assoc Thail 99:331–337Google Scholar
  9. 9.
    Lam KY, Law SY, So MK, Fok M, Ma LT, Wong J (1996) Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma. Cancer 77:7–13CrossRefGoogle Scholar
  10. 10.
    Law AK, Lam KY, Lam FK, Wong TK, Poon JL, Chan FH (2003) Image analysis system for assessment of immunohistochemically stained proliferative marker (MIB-1) in oesophageal squamous cell carcinoma. Comput Methods Prog Biomed 70:37–45CrossRefGoogle Scholar
  11. 11.
    Islam F, Gopalan V, Law S, Tang JC, Lam AK (2019) FAM134B promotes esophageal squamous cell carcinoma in vitro and its correlations with clinicopathologic features. Hum Pathol 87:1–10.  https://doi.org/10.1016/j.humpath.2018.11.033CrossRefPubMedGoogle Scholar
  12. 12.
    Yu VZ, Wong VC, Dai W, Ko JM, Lam AK, Chan KW, Samant RS, Lung HL, Shuen WH, Law S, Chan YP, Lee NP, Tong DK, Law TT, Lee VH, Lung ML (2015) Nuclear localization of dnajb6 is associated with survival of patients with esophageal cancer and reduces AKT signaling and proliferation of cancer cells. Gastroenterology 149:1825–1836.  https://doi.org/10.1053/j.gastro.2015.08.025CrossRefPubMedGoogle Scholar
  13. 13.
    Li B, Xu WW, Lam AKY, Wang Y, Hu HF, Guan XY, Qin YR, Saremi N, Tsao SW, He QY, Cheung ALM (2017) Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget 8:38755–38766.  https://doi.org/10.18632/oncotarget.16333CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Chai AW, Cheung AK, Dai W, Ko JM, Ip JC, Chan KW, Kwong DL, Ng WT, Lee AW, Ngan RK, Yau CC, Tung SY, Lee VH, Lam AK, Pillai S, Law S, Lung ML (2016) Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Oncotarget 7:78859–78871.  https://doi.org/10.18632/oncotarget.12889CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Xu WW, Li B, Lam AK, Tsao SW, Law SY, Chan KW, Yuan QJ, Cheung AL (2015) Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget 6:1790–1805PubMedGoogle Scholar
  16. 16.
    Chan D, Tsoi MY, Liu CD, Chan SH, Law SY, Chan KW, Chan YP, Gopalan V, Lam AK, Tang JC (2013) Oncogene GAEC1 regulates CAPN10 expression which predicts survival in esophageal squamous cell carcinoma. World J Gastroenterol 19:2772–2780.  https://doi.org/10.3748/wjg.v19.i18.2772.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ng HY, Li J, Tao L, Lam AK, Chan KW, Ko JMY, Yu VZ, Wong M, Li B, Lung ML (2018) Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR/ERK activation. Transl Oncol 11:1323–1333.  https://doi.org/10.1016/j.tranon.2018.08.005CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Saremi N, Lam AK (2018) Application of tissue microarray in esophageal adenocarcinoma. Methods Mol Biol 1756:105–118.  https://doi.org/10.1007/978-1-4939-7734-5_10CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Cancer Molecular Pathology, School of MedicineGriffith UniversityGold CoastAustralia
  2. 2.Cancer Molecular Pathology of School of MedicineGriffith UniversityGold CoastAustralia

Personalised recommendations